控制危险因素对中国未来肝癌死亡的潜在影响

IF 7 2区 医学 Q1 ONCOLOGY
Mengdi Cao, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Tingting Zuo, Tianyi Li, Yuanjie Zheng, Changfa Xia, Wanqing Chen
{"title":"控制危险因素对中国未来肝癌死亡的潜在影响","authors":"Mengdi Cao, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Tingting Zuo, Tianyi Li, Yuanjie Zheng, Changfa Xia, Wanqing Chen","doi":"10.21147/j.issn.1000-9604.2025.03.08","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to quantify the potential impact of controlling major risk factors on liver cancer deaths in China from 2021 to 2050 under various intervention scenarios.</p><p><strong>Methods: </strong>We developed a macro-level simulation model based on comparative risk assessment to estimate population attributable fractions and avoidable liver cancer deaths. Risk factor prevalence data were obtained from national surveys and epidemiological estimates. Three intervention scenarios for each risk factor were projected: elimination (Scenario 1), ambitious reduction (Scenario 2), and manageable targets aligned with national/global goals (Scenario 3). The impact of secondary prevention through liver cancer screening at different coverage was evaluated.</p><p><strong>Results: </strong>Between 2021 and 2050, liver cancer deaths in China are projected to reach 9.44 million in males and 4.29 million in females. Eliminating hepatitis B virus and hepatitis C virus could prevent 65.62% (57.47%-73.77%) and 28.47% (24.93%-32.00%) of liver cancer deaths, respectively. Achieving manageable targets in reducing the prevalence of smoking and alcohol drinking could prevent 6.57% (5.75%-7.38%) and 0.85% (0.75%-0.96%) of liver cancer deaths, with a more pronounced effect observed in males. Eliminating high body mass index (BMI) could avert 45,000 male and 25,000 female deaths annually by 2050, while diabetes elimination could prevent 60,000 male and 21,000 female deaths. Secondary prevention through liver cancer screening with 80% coverage could reduce liver cancer deaths by 3.59% (3.14%-4.04%) for the total population. Combining all interventions under Scenario 1 could prevent up to 88.39% (76.65%-99.81%) of male and 77.80% (67.42%-87.88%) of female liver cancer deaths by 2050.</p><p><strong>Conclusions: </strong>Comprehensive risk factor control could prevent over 80% of liver cancer deaths in China by 2050. Secondary prevention through screening may offer modest additional benefits. These findings provide strong quantitative support for targeted, evidence-based interventions and underscore the need for policy action to address key risk factors.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"37 3","pages":"390-403"},"PeriodicalIF":7.0000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240244/pdf/","citationCount":"0","resultStr":"{\"title\":\"Potential impact of controlling risk factors on future liver cancer deaths in China.\",\"authors\":\"Mengdi Cao, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Tingting Zuo, Tianyi Li, Yuanjie Zheng, Changfa Xia, Wanqing Chen\",\"doi\":\"10.21147/j.issn.1000-9604.2025.03.08\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aims to quantify the potential impact of controlling major risk factors on liver cancer deaths in China from 2021 to 2050 under various intervention scenarios.</p><p><strong>Methods: </strong>We developed a macro-level simulation model based on comparative risk assessment to estimate population attributable fractions and avoidable liver cancer deaths. Risk factor prevalence data were obtained from national surveys and epidemiological estimates. Three intervention scenarios for each risk factor were projected: elimination (Scenario 1), ambitious reduction (Scenario 2), and manageable targets aligned with national/global goals (Scenario 3). The impact of secondary prevention through liver cancer screening at different coverage was evaluated.</p><p><strong>Results: </strong>Between 2021 and 2050, liver cancer deaths in China are projected to reach 9.44 million in males and 4.29 million in females. Eliminating hepatitis B virus and hepatitis C virus could prevent 65.62% (57.47%-73.77%) and 28.47% (24.93%-32.00%) of liver cancer deaths, respectively. Achieving manageable targets in reducing the prevalence of smoking and alcohol drinking could prevent 6.57% (5.75%-7.38%) and 0.85% (0.75%-0.96%) of liver cancer deaths, with a more pronounced effect observed in males. Eliminating high body mass index (BMI) could avert 45,000 male and 25,000 female deaths annually by 2050, while diabetes elimination could prevent 60,000 male and 21,000 female deaths. Secondary prevention through liver cancer screening with 80% coverage could reduce liver cancer deaths by 3.59% (3.14%-4.04%) for the total population. Combining all interventions under Scenario 1 could prevent up to 88.39% (76.65%-99.81%) of male and 77.80% (67.42%-87.88%) of female liver cancer deaths by 2050.</p><p><strong>Conclusions: </strong>Comprehensive risk factor control could prevent over 80% of liver cancer deaths in China by 2050. Secondary prevention through screening may offer modest additional benefits. These findings provide strong quantitative support for targeted, evidence-based interventions and underscore the need for policy action to address key risk factors.</p>\",\"PeriodicalId\":9882,\"journal\":{\"name\":\"Chinese Journal of Cancer Research\",\"volume\":\"37 3\",\"pages\":\"390-403\"},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2025-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240244/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese Journal of Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21147/j.issn.1000-9604.2025.03.08\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2025.03.08","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在量化不同干预情景下控制主要危险因素对2021 - 2050年中国肝癌死亡的潜在影响。方法:我们建立了一个基于比较风险评估的宏观模拟模型,以估计人群归因分数和可避免的肝癌死亡。危险因素流行率数据来自国家调查和流行病学估计。对每个风险因素预测了三种干预情景:消除(情景1)、大幅度减少(情景2)和与国家/全球目标一致的可管理目标(情景3)。评估了不同覆盖率的肝癌筛查对二级预防的影响。结果:2021年至2050年,中国肝癌死亡人数预计将达到944万男性和429万女性。消除乙肝病毒和丙肝病毒可分别预防65.62%(57.47% ~ 73.77%)和28.47%(24.93% ~ 32.00%)的肝癌死亡。实现降低吸烟和饮酒流行率的可控目标可以预防6.57%(5.75%-7.38%)和0.85%(0.75%-0.96%)的肝癌死亡,在男性中观察到的效果更为明显。到2050年,消除高身体质量指数(BMI)每年可避免4.5万名男性和2.5万名女性死亡,而消除糖尿病可防止6万名男性和2.1万名女性死亡。肝癌筛查的二级预防覆盖率达到80%,可使总人口的肝癌死亡率降低3.59%(3.14%-4.04%)。结合情景1下的所有干预措施,到2050年可预防高达88.39%(76.65%-99.81%)的男性和77.80%(67.42%-87.88%)的女性肝癌死亡。结论:到2050年,综合危险因素控制可预防中国80%以上的肝癌死亡。通过筛查进行的二级预防可能提供适度的额外益处。这些研究结果为有针对性的、以证据为基础的干预措施提供了强有力的定量支持,并强调了采取政策行动解决关键风险因素的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Potential impact of controlling risk factors on future liver cancer deaths in China.

Objective: This study aims to quantify the potential impact of controlling major risk factors on liver cancer deaths in China from 2021 to 2050 under various intervention scenarios.

Methods: We developed a macro-level simulation model based on comparative risk assessment to estimate population attributable fractions and avoidable liver cancer deaths. Risk factor prevalence data were obtained from national surveys and epidemiological estimates. Three intervention scenarios for each risk factor were projected: elimination (Scenario 1), ambitious reduction (Scenario 2), and manageable targets aligned with national/global goals (Scenario 3). The impact of secondary prevention through liver cancer screening at different coverage was evaluated.

Results: Between 2021 and 2050, liver cancer deaths in China are projected to reach 9.44 million in males and 4.29 million in females. Eliminating hepatitis B virus and hepatitis C virus could prevent 65.62% (57.47%-73.77%) and 28.47% (24.93%-32.00%) of liver cancer deaths, respectively. Achieving manageable targets in reducing the prevalence of smoking and alcohol drinking could prevent 6.57% (5.75%-7.38%) and 0.85% (0.75%-0.96%) of liver cancer deaths, with a more pronounced effect observed in males. Eliminating high body mass index (BMI) could avert 45,000 male and 25,000 female deaths annually by 2050, while diabetes elimination could prevent 60,000 male and 21,000 female deaths. Secondary prevention through liver cancer screening with 80% coverage could reduce liver cancer deaths by 3.59% (3.14%-4.04%) for the total population. Combining all interventions under Scenario 1 could prevent up to 88.39% (76.65%-99.81%) of male and 77.80% (67.42%-87.88%) of female liver cancer deaths by 2050.

Conclusions: Comprehensive risk factor control could prevent over 80% of liver cancer deaths in China by 2050. Secondary prevention through screening may offer modest additional benefits. These findings provide strong quantitative support for targeted, evidence-based interventions and underscore the need for policy action to address key risk factors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
9.80%
发文量
1726
审稿时长
4.5 months
期刊介绍: Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013. CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信